Elsevier

Clinical Breast Cancer

Volume 8, Issue 5, October 2008, Pages 449-452
Clinical Breast Cancer

Case Report
Immunomodulatory Therapy in Multiple Sclerosis and Breast Cancer Risk: A Case Report and Literature Review

https://doi.org/10.3816/CBC.2008.n.055Get rights and content

Abstract

Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system frequently complicated by devastating neurologic symptoms and progressive disability. Much progress has been made in the development of immunomodulating drugs to help fight the progression of MS. These drugs are believed to work by interacting with various immune system components to reduce the amount of autoimmune destruction to the nervous system. We report 2 cases of women with MS on immunomodulatory therapy who presented with locally advanced breast cancer with aggressive biologic phenotypes and exceptionally poor outcomes. We consider the potential for an increased risk of developing a poorer-prognosis breast cancer as a result of concomitant immunomodulatory effects of the previous MS treatment, particularly the effects the drugs are reported to have on regulatory T cells, and therefore present these cases and a review of the current literature. Current data in the literature reflect the need for further study in ascertaining the risk of biologically poor-prognosis breast cancer development in patients with MS treated with immunomodulatory therapy.

References (33)

  • MA Kriegel et al.

    Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II

    J Exp Med

    (2004)
  • MR Ehrenstein et al.

    Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy

    J Exp Med

    (2004)
  • S Lindley et al.

    Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes

    Diabetes

    (2005)
  • The INFB Multiple Sclerosis Study Group

    Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial

    Neurology

    (1995)
  • LD Jacobs et al.

    Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

    Ann Neurol

    (1996)
  • PRISMS (Prevention of Relapse and Disability by Interferon β-1b Subcutaneously in Multiple Sclerosis) Study Group

    Randomized double-blind placebo controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis

    Lancet

    (1998)
  • Cited by (7)

    View all citing articles on Scopus

    Electronic forwarding or copying is a violation of US and International Copyright Laws.

    Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1526-8209, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.

    View full text